HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

LFCR

Lifecore Biomedical, Inc.

Healthcare — Drug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Buy 2.0 / 5 3 analysts
$6.53
$-0.05 (-0.76%)
Target: $6.83 (4.6%)

Price History

52-Week Range
Sign in to add LFCR to a watchlist or set price alerts.

Fundamentals

Market Cap$165.79M
P/E Ratio (TTM)-
Forward P/E-5.39
EPS (TTM)$-1.27
Dividend Yield-
Profit Margin-23.78%
Revenue Growth-
ROE-
Debt/Equity722.60
Recommendation Buy 2.0
Analyst Target$6.83
Analysts3
Next Earnings Aug 5, 2026 BMO
Indexes -

Technical Indicators

RSI (14)41.5
Beta1.06
SMA 20$4.61
SMA 40$5.05
52-Week High$8.98
52-Week Low$3.63
50-Day Avg$5.04
200-Day Avg$6.24
Avg Volume197.8K
Volume77.8K

Performance Analysis

BULLISH

LFCR shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 54% of its 52-week range.
~ RSI at 41.5 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Operating at a loss with -23.8% margin.
+ Wall Street consensus is "Buy" from 3 analysts.
+ Average analyst target of $6.83 implies 4.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 04:15 UTC

Back to Screener Export Report